1. Home
  2. RMT vs GERN Comparison

RMT vs GERN Comparison

Compare RMT & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Royce Micro-Cap Trust Inc.

RMT

Royce Micro-Cap Trust Inc.

HOLD

Current Price

$13.51

Market Cap

722.0M

Sector

Finance

ML Signal

HOLD

Logo Geron Corporation

GERN

Geron Corporation

HOLD

Current Price

$1.26

Market Cap

821.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RMT
GERN
Founded
1993
1990
Country
United States
United States
Employees
N/A
258
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
722.0M
821.1M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
RMT
GERN
Price
$13.51
$1.26
Analyst Decision
Hold
Analyst Count
0
3
Target Price
N/A
$2.17
AVG Volume (30 Days)
101.3K
14.2M
Earning Date
01-01-0001
05-06-2026
Dividend Yield
7.37%
N/A
EPS Growth
N/A
N/A
EPS
1.49
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$26.91
Revenue Next Year
N/A
$43.75
P/E Ratio
$8.94
N/A
Revenue Growth
N/A
N/A
52 Week Low
$8.65
$1.04
52 Week High
$13.97
$2.01

Technical Indicators

Market Signals
Indicator
RMT
GERN
Relative Strength Index (RSI) 58.43 32.94
Support Level $10.32 $1.24
Resistance Level $13.97 $1.29
Average True Range (ATR) 0.27 0.09
MACD -0.08 -0.02
Stochastic Oscillator 54.13 10.42

Price Performance

Historical Comparison
RMT
GERN

About RMT Royce Micro-Cap Trust Inc.

Royce Micro-Cap Trust Inc is a diversified closed-end investment company. The company is engaged in investing in micro-cap securities. It invests in the consumer discretionary sector, including diversified consumer services, hotels, household durables, leisure products, and luxury goods. Consumer staples sector, including beverages, food, and staples retailing, food products, and personal products, Energy sector, including energy equipment and services, and oil, gas, and consumable fuels. The company also invests in other sectors, including healthcare, financials, industrials, IT, telecommunications, and materials.

About GERN Geron Corporation

Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other hematologic malignancies. The company operates as a single segment, being the development of therapeutic products for oncology.

Share on Social Networks: